ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a buy rating to a hold rating in a report published on Wednesday,Wall Street Zen reports.

A number of other analysts have also recently weighed in on ACAD. HC Wainwright decreased their target price on shares of ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, September 25th. TD Cowen reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 24th. BMO Capital Markets cut their target price on ACADIA Pharmaceuticals from $36.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, September 24th. Stifel Nicolaus upped their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $35.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, October 19th. Thirteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.55.

ACADIA Pharmaceuticals Stock Down 0.0%

ACAD stock opened at $21.23 on Wednesday. ACADIA Pharmaceuticals has a 12-month low of $18.39 and a 12-month high of $30.96. The company’s fifty day simple moving average is $22.86 and its 200 day simple moving average is $23.59. The firm has a market cap of $3.66 billion, a price-to-earnings ratio of 10.06 and a beta of 0.87.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11. The business had revenue of $342.30 million for the quarter, compared to the consensus estimate of $332.58 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%. The business’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.42 earnings per share. Research analysts expect that ACADIA Pharmaceuticals will post 0.66 earnings per share for the current year.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 3,321 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares in the company, valued at $1,489,203.36. This represents a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 26.20% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in ACADIA Pharmaceuticals during the second quarter valued at $569,634,000. First Trust Advisors LP boosted its position in ACADIA Pharmaceuticals by 47.3% in the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after purchasing an additional 1,073,834 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in ACADIA Pharmaceuticals by 8.0% during the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock worth $70,222,000 after buying an additional 234,186 shares during the period. Palo Alto Investors LP purchased a new position in ACADIA Pharmaceuticals in the second quarter valued at approximately $72,461,629. Finally, Renaissance Technologies LLC boosted its position in ACADIA Pharmaceuticals by 12.5% during the first quarter. Renaissance Technologies LLC now owns 1,724,196 shares of the biopharmaceutical company’s stock worth $38,381,000 after purchasing an additional 191,600 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: RBC raised its price target to $41 from $31 and maintained an Outperform rating, citing continued momentum for Daybue. RBC price-target update RBC Daybue commentary
• Positive Sentiment: Canaccord Genuity raised its target to $38 from $36 and reiterated a Buy rating, adding to the favorable analyst outlook. Canaccord analyst recommendations
• Positive Sentiment: ACADIA reported Q3 revenue of $342.3 million, above the roughly $332.6 million consensus, and earnings of $0.31 per share, ahead of estimates around $0.19–$0.20. Revenue increased 22.8% year over year, reinforcing the company’s growth story. Q3 earnings results
• Neutral Sentiment: The company revised its 2026 earnings guidance, but the provided report headline does not disclose the direction or magnitude of the change. Investors will need the detailed guidance to assess its implications. 2026 earnings guidance update

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.